Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 38.97M -16.2% |
| Revenue (ttm) | 90,000 |
| Net Income | -23.47M |
| EPS | -0.76 |
| Shares Out | 31.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,555 |
| Open | 1.270 |
| Previous Close | 1.280 |
| Day's Range | 1.250 - 1.327 |
| 52-Week Range | 0.952 - 1.945 |
| Beta | -0.11 |
| Analysts | Buy |
| Price Target | 5.00 (+300.0%) |
| Earnings Date | May 8, 2026 |
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 300.00% from the latest price.
News
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its development as a mutation-agnostic therapy in settings whereresistance to EGFR- and KRAS-targeted a...
Actinium presents data from Actimab-A studies at AACR
Actinium Pharmaceuticals (ATNM) highlighted data presented at the American Association for Cancer Research, or AACR, Annual Meeting supporting transcriptional reprogramming as a central mechanism driv...
Actinium presents preclinical results for ATNM-400 at AACR
Actinium Pharmaceuticals (ATNM) announced preclinical results for ATNM-400 across prostate, lung, and breast cancer models presented at the American Association for Cancer Research, or AACR, Annual Me...
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies inc...
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential In prostate cancer, ATNM-400 demonstrates efficacy across bo...
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company, today announced that it received notice of the U.S. Food & Drug Administration's...
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic eff...
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research
ATHENS, Greece & BELOIT, Wisc.--(BUSINESS WIRE)--BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply ...
Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400
Actinium Pharmaceuticals (ATNM) announced the presentation of new preclinical data for ATNM-400, its first-in-class Actinium-225 based antibody radioconjugate, at the 2025 San Antonio Breast Cancer Sy...
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HE...
Actinium Pharmaceuticals announces preclinical data for ATNM-400
Actinium Pharmaceuticals (ATNM) announced preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in hormone receptor positive, HER2 positive and triple-negative breast c...
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a...
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at th...
Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity
Actinium Pharmaceuticals (ATNM) announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer, or NSCLC. ATNM-400 is Actinium’s lead solid tumor program, whic...
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) an...
Actinium presents preclinical data for ATNM-400
Actinium Pharmaceuticals (ATNM) highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225, or Ac-225, at the 32n...
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling po...
Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program
Actinium Pharmaceuticals (ATNM) announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer has been accepted for presentation at the AACR-NCI-EORTC Internat...
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinica...
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression...
Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer
Actinium Pharmaceuticals (ATNM) reported additional preclinical data supporting its ATNM-400 radiotherapy prostate cancer candidate at the 4th Annual Targeted Radiopharmaceuticals Summit in San Diego....
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto ® and enzalutamide, follow-up continues - ATNM-400 significantly improved survival ...
Actinium highlights expanded data set for ATNM-400 in prostate cancer
Actinium Pharmaceuticals (ATNM) reported new preclinical data from its non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225...
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ATNM-...
Actinium Pharmaceuticals Transcript: Life Sciences Investor Forum
The conference highlighted a robust pipeline in targeted radiotherapy, with lead programs advancing in AML, solid tumors, and cell/gene therapy. Promising clinical data, large market opportunities, and a strong financial position support continued growth and partnership opportunities.